Toute l’équipe de 4P-Pharma est fière d’annoncer que le Pr Francis Berenbaum a remporté le prix Fondation Guillaumat-Piel 2020 de la Fondation pour la Recherche Médicale (FRM) pour ses travaux sur les maladies ostéo-articulaires !
Nous collaborons avec Francis Berenbaum depuis plusieurs années sur le développement de 4P004, notre solution thérapeutique pour enrayer l’arthrose.
Francis Berenbaum est professeur de rhumatologie à la Faculté de médecine Sorbonne Université, chef du service de Rhumathologie de l’hôpital Saint-Antoine AP-HP et responsable de l’équipe « maladies métaboliques et pathologies liées au vieillissement » (UMR-S-938, Inserm).
Pr. Francis Berenbaum (Head of Rheumatology at Saint-Antoine Hospital, and Professor of Rheumatology at Sorbonne University, in Paris, France) will present a poster on 4P004 entitled “Liraglutide as a Potential Intra-Articular Treatment for Cartilage Regeneration in Osteoarthritis: In Vitro and In Vivo Studies Supporting a Pro-Chondrogenic Effect” (#0703) during the ACR Convergence 2020 annual meeting, November 5-9, 2020, online.
4P-Pharma, a biotechnology company specialised in the sourcing and the development of early stage therapeutic molecules, announced the appointment of Sonia Escaich, PhD, as Chief Operating Officer.
“Sonia has deep domain expertise from both drug development and business perspective, she will bring a wealth of experience to the team”, said Revital Rattenbach, Founder and President of 4P-Pharma. “[…] I have full confidence that she will help accelerate our scientific programs development and operational efficiencies that will take 4P-Pharma to the next level.”
“[…] This is indeed a great time for 4P-Pharma and I look forward to [Sonia’s] strong professional support to all of our R&D operations as well as funding opportunities”, added Dr. Patrice Denèfle, Chief Scientific Officer of 4P-Pharma.
“[…] I am delighted to join 4P-Pharma dynamic team, and to participate to the development of its therapeutic innovations in fields with high medical needs.”, said Dr. Sonia Escaich.
4P-Pharma, a biotechnology company specialised in the sourcing and the development of early stage therapeutic molecules, announces the appointment of Patrice Denèfle, PhD, HDR, Adjunct Prof., as its Chief Scientific Officer (CSO).
“We are delighted to welcome Patrice to our team as Chief Scientific Officer. […] I look forward to work closely with him to push forward 4P-Pharma’s strong momentum”, said Revital Rattenbach, Founder and President of 4P-Pharma.
“I am thrilled to join 4P-Pharma team as CSO, as the company has a very impressive record of innovative projects. […] I am looking forward to work with all the team of 4P-Pharma and its scientific and advisory board to support and boost the clinical development of 4P004 and bring my expertise to expand 4P-Pharma’s portfolio drug candidates”, said Patrice Denèfle.
4P-Pharma received the Seal of Excellence from the European Commission for its application related to the development of a disease modifier treatment for osteoarthritis, 4P-004 to the Horizon 2020 EIC Accelerator (SME instrument).
Following evaluation by an international panel of independent experts, 4P-Pharma’s project was scored as a high-quality proposal in this highly competitive evaluation process, passing all their stringent assessment thresholds for the 3 award criteria (i.e. excellence, impact and implementation).